CENTURY THERAPEUTICS INC. - COMMON STOCK

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders

21 Jan 2025 06:00:19 By Nasdaq GlobeNewswire

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

26 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

05 Nov 2024 08:05:00 By Nasdaq GlobeNewswire

Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting

05 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference

04 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer

26 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

08 Aug 2024 06:30:00 By Nasdaq GlobeNewswire

Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

03 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting

10 May 2024 06:00:00 By Nasdaq GlobeNewswire

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

09 May 2024 06:30:00 By Nasdaq GlobeNewswire

Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

23 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

11 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

08 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

19 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

14 Mar 2024 06:30:00 By Nasdaq GlobeNewswire

Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

05 Mar 2024 17:03:06 By Nasdaq GlobeNewswire

Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

01 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

09 Dec 2023 11:00:00 By Nasdaq GlobeNewswire

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

06 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

06 Dec 2023 06:30:00 By Nasdaq GlobeNewswire